Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT04582344	Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)		Recruiting	No Results Available	COVID-19	Biological: CoronaVac|Biological: Placebo	Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19|Protection Indexes of One Vaccine Dose For Symptomatic COVID-19|Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity/and Death|Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection|Safety indexes of adverse reactions in 28 days|Safety indexes of adverse reactions in 7 days|Safety indexes of serious adverse events in 1 year|Immunogenicity parameters (seroconversion rate, seropositivity rate) in 14 days|Immunogenicity parameters (seroconversion rate, seropositivity rate) in 28 days|Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 14 days|Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 28 days	Health Institutes of Turkey	All	18 Years to 59 Years   (Adult)	Phase 3	13000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	9026-ASI	September 14, 2020	February 15, 2021	April 15, 2021	October 9, 2020		October 9, 2020	T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic, Ankara, Turkey Region, Turkey|T.R. Ministry of Health Ankara Provincial Health Directorate Ankara Training and Research Hospital, Infectious Diseases, Ankara, Turkey Region, Turkey|Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey Region, Turkey|Çukurova University Faculty of Medicine, Department of Infectious Diseases, Adana, Turkey|Hacettepe University Faculty of Medicine Department of Infections Diseases and Clinical Microbiology, Ankara, Turkey|T.C Ministry of Health Ankara Provincial Health Directorate Health Sciences University Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey|Bursa Uludağ University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bursa, Turkey|Dicle University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Diyarbakır, Turkey|Gaziantep University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Gaziantep, Turkey|Acıbadem Atakent Hospital, Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|Altınbaş University Medical Park Bahçelievler Infectious Diseases and Microbiology, Istanbul, Turkey|Cerrahpaşa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|Istanbul Medipol University Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey|Istanbul University Istanbul Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|T.R. Ministry of Health Istanbul Provincial Health Directorate Marmara Univesity Istanbul Pendik Education and Research Hospital, Istanbul, Turkey|T.R. Ministry of Health Istanbul Provincial Health Directorate Prof. Dr. Cemil Taşçıoğlu City Hospital, Infectious Diseases Clinic, Istanbul, Turkey|T.R. Ministry of Health Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey|Ege University Faculty of Medicine Hospital, Department of Infectious Diseasesaculty of Medicine Hospital, Department of Infectious Diseases, İzmir, Turkey|Republic Of Turkey Ministry Of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital, İzmir, Turkey|T.R. Ministry of Health İzmir Provincial Health Directorate İzmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases, İzmir, Turkey|T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department, Kayseri, Turkey|Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Kocaeli, Turkey|Malatya İnönü University Faculty of Medicine, Department of Infectious Diseases, Malatya, Turkey|Karadeniz Technical University Medical Faculty Hospital, Department of Infectious Diseases and Clinical Microbiology, Trabzon, Turkey		https://ClinicalTrials.gov/show/NCT04582344
2	NCT04564716	Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus		Recruiting	No Results Available	Covid19	Biological: Gam-COVID-Vac|Other: Placebo	percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose|the severity of the clinical course of COVID-19|Changing of antibody levels against the SARS-CoV-2 glycoprotein S|Incidence of adverse events in trial subjects|Severity of adverse events in trial subjects	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|RDIF (Russian Direct Investment Fund)|CRO: iPharma	All	18 Years to 60 Years   (Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	04-Gam-COVID-Vac-2020-RB	September 28, 2020	March 28, 2021	April 10, 2021	September 25, 2020		October 1, 2020	Health Institution "14th Central Regional Polyclinic of the Partisan district of Minsk", Minsk, Belarus|Health Institution "19th Central Regional Polyclinic of the Pervomaysk district of Minsk", Minsk, Belarus|Health Institution "1st Central Regional Clinical Polyclinic of the Central district of Minsk", Minsk, Belarus|Health Institution "28th Regional Polyclinic of Minsk", Minsk, Belarus|Health Institution "4th City Polyclinic of Minsk", Minsk, Belarus|Health Institution "5th City Clinical Polyclinic of Minsk", Minsk, Belarus|Health Institution "Minsk Order of the Red Banner of Labor Regional Clinical Hospital, Minsk, Belarus|Health Institution "Vitebsk Regional Clinical Hospital", Vitebsk, Belarus		https://ClinicalTrials.gov/show/NCT04564716
3	NCT04560881	Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)		Recruiting	No Results Available	COVID-19 Virus Infection	Biological: Inactivated SARS-CoV-2 vaccine (Vero cell)|Biological: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine	Incidence of COVID-19 cases after two-doses of vaccination|The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Increase (GMI) of anti-SARS-CoV-2 neutralizing antibody|Incidence of any adverse reactions/events|Incidence of adverse reactions/events|Incidence of serious adverse events (SAE)	Laboratorio Elea Phoenix S.A.|Beijing Institute of Biological Products Co., Ltd|China National Biotec Group Company Limited|The Huesped Foundation	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	3000	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	BIBP2020003AR	September 16, 2020	December 1, 2021	December 1, 2021	September 23, 2020		October 5, 2020	Fundación Huésped, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Vacunar Liniers, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Vacunar Cañitas, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Vacunar Coghlan, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina		https://ClinicalTrials.gov/show/NCT04560881
4	NCT04540419	Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19		Recruiting	No Results Available	Covid19	Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo	Superiority of the vaccine Ad5-nCoV to placebo by the level of seroconversion|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (titer of SARS-CoV-2 antibodies)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (level of seroconversion)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (rise of SARS-CoV-2 antibodies)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (T-cell response)|Frequency of confirmed COVID-19|Frequency of confirmed cases of COVID-19, requiring hospitalization|Frequency of cases with severe course of COVID-19|Frequency of death due to COVID-19.|Reactogenicity of the vaccine Ad5-nCoV compared with placebo|Frequency and character of adverse events and serious adverse events.|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (blood pressure)|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (heart rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (respiratory rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of physical examination|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography (Heart rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry (enzymes)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hemoglobin)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hematocrit)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocytes)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocyte sedimentation rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram (fibrinogen)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (relative density)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (pH)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (protein)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (glucose)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of determination of immunoglobulin E serum concentrations.	NPO Petrovax|CanSino Biologics Inc.	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	500	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	Prometheus_Rus	September 11, 2020	November 30, 2020	July 31, 2021	September 7, 2020		September 17, 2020	Municipal budgetary institution "Central City Hospital No. 7", Ekaterinburg, Russian Federation|Federal budgetary institution of science "Central Research Institute of Epidemiology" of the Federal Service for Surveillance on Consumer Rights Protectionand Human Welfare, Moscow, Russian Federation|State Budgetary Institution of Healthcare of the City of Moscow "City Polyclinic No. 2of the Department of Healthcare of the City of Moscow", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education "First MoscowState Medical University named after I.M. Sechenov "of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Limited Liability Company "Research Center Eco-safety", Saint Petersburg, Russian Federation|Federal State Budgetary Institution "Research Institute of Influenza named after A.A.Smorodintsev "of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation|Private health care institution "Clinical hospital 'Russian Railways - Medicine' of the city of Yaroslavl", Yaroslavl, Russian Federation		https://ClinicalTrials.gov/show/NCT04540419
5	NCT04540393	AZD1222 Vaccine for the Prevention of COVID-19		Not yet recruiting	No Results Available	COVID-19	Biological: AZD1222	Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability].|Incidence of Solicited AEs for 7 following each vaccination [Safety and Tolerability].|SARS-CoV-2 antigen-specific antibody levels|The rate of participants seroconverting from negative to positive SARS-CoV-2 S antigen|The rate of participants seroconverting from negative to positive SARS-CoV-2 N|Quantity of SARS-CoV-2 neutralizing antibodies|Count of peripheral blood mononuclear cells (PBMCs)|Quantity of seasonal coronavirus antigens|Quantity of antibodies to the ChAdOx1vector and the persistence of these antibodies over time	AstraZeneca|Iqvia Pty Ltd|Covance	All	18 Years and older   (Adult, Older Adult)	Phase 3	100	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	D8111C00001	August 26, 2020	March 5, 2021	March 5, 2021	September 7, 2020		September 7, 2020	Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation		https://ClinicalTrials.gov/show/NCT04540393
6	NCT04530396	Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19	RESIST	Recruiting	No Results Available	Covid19 Prevention	Biological: Gam-COVID-Vac|Other: placebo	percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose|the severity of the clinical course of COVID-19|Changing of antibody levels against the SARS-CoV-2 glycoprotein S|Changing of antigen-specific cellular immunity level|Changing of of virus neutralizing antibody titer|Incidence of adverse events in trial subjects|Severity of adverse events in trial subjects	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Government of the city of Moscow|CRO: Crocus Medical BV	All	18 Years to 111 Years   (Adult, Older Adult)	Phase 3	40000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	04-Gam-COVID-Vac-2020	September 7, 2020	May 1, 2021	May 1, 2021	August 28, 2020		September 23, 2020	ARCHIMED V Clinic of new medical technologies limited liability company, Moscow, Russian Federation|Hadassah LTD, Moscow, Russian Federation|Medsi Group of companies joint-stock company", Moscow, Russian Federation|Niarmedic Plus, Moscow, Russian Federation|State budgetary healthcare institution of the city of Moscow "City clinical hospital No. 52 of the Moscow city health Department", Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Consultation and Diagnosis Polyclinic No. 121, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, M. Konchalovsky Municipal Clinical Hospital, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, M. Zhadkevich Municipal Clinical Hospital, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 115, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 2, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 210, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 212, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 219, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 220, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Municipal Polyclinic No. 62, Moscow Healthcare Department, Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow " city polyclinic No. 109 Of the Department of health of the city of Moscow", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow " city polyclinic No. 170 Of the Department of health of the city of Moscow", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow " city polyclinic No. 36 Of the Department of health of the city of Moscow", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow " city polyclinic No. 46 Of the Department of health of the city of Moscow", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow " city polyclinic No. 6 Of the Department of health of the city of Moscow", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow " city polyclinic No. 68 Of the Department of health of the city of Moscow", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "Diagnostic center No. 5 with polyclinic Department Of the Department of health of the city of Moscow", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "Diagnostic clinical center No. 1 Of the Department of health of the city of Moscow", Moscow, Russian Federation		https://ClinicalTrials.gov/show/NCT04530396
7	NCT04526990	Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above		Recruiting	No Results Available	COVID-19	Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo	Incidence of COVID-19 cases|Incidence of SAE|Incidence of severe COVID-19 cases|Incidence of solicited adverse reactions|Incidence of unsolicited adverse events|Immunogencity of S-RBD IgG antibody (ELISA method)|Immunogencity of neutralizing antibody|Cell-mediated immune profile	CanSino Biologics Inc.|Beijing Institute of Biotechnology	All	18 Years and older   (Adult, Older Adult)	Phase 3	40000	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	CS-CTP-AD5NCOV-Ⅲ	September 15, 2020	December 30, 2021	January 30, 2022	August 26, 2020		September 16, 2020	Shaukat Khanum Memorial Cancer Hospital and Research Centre, Islamabad, Norhern Punajb Rawalpindi, Pakistan		https://ClinicalTrials.gov/show/NCT04526990
8	NCT04516746	Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults		Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2	Biological: AZD1222|Biological: Placebo	To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age|To assess the safety and tolerability of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age|To assess the reactogenicity of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age (Substudy only)|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of SARS-CoV-2 asymptomatic infection|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of symptomatic COVID-19 using CDC criteria|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of University of Oxford defined symptomatic COVID-19|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of severe or critical symptomatic COVID-19|To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19-related Emergency Department visits|To assess antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or placebo (Substudy and Illness Visits only)|To determine anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or placebo (Sub-study and Illness Visits only)	AstraZeneca|Iqvia Pty Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	30000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	D8110C00001	August 17, 2020	December 2, 2020	October 5, 2022	August 18, 2020		August 18, 2020	Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Torrance, California, United States|Research Site, Atlantis, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bloomington, Minnesota, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04516746
9	NCT04505722	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants	ENSEMBLE	Recruiting	No Results Available	Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol	Biological: Ad26.COV2.S|Other: Placebo	Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19) with Seronegative Status|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of their Serostatus|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease COVID-19 Regardless of Their Serostatus|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19)|Number of Participants with First Occurrence of COVID-19 Requiring Medical Intervention|SARS-CoV-2 Viral Load as Assessed by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) in Participants with Molecularly Confirmed, Moderate to Severe/Critical COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed Mild COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed COVID-19 Defined by the US Food and Drug Administration (FDA) Harmonized case Definition|Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19|Serologic Conversion Between Baseline and (Day 1; Pre-vaccination), Day 71, 6 Months and 1- Year Post-vaccination using an Enzyme-linked Immunosorbent Assay (ELISA)|Number of Participants with First Occurrence of SARS-CoV-2 Infection (Serologically and/or Molecularly Confirmed)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs) Leading to Study Discontinuation|Number of Participants with Solicited Local Adverse Events (AEs) During 7 Days Following Vaccination|Number of Participants with Solicited Systemic AEs During 7 Days Following Vaccination|Number of Participants with Unsolicited Local Adverse Events (AEs) During 28 Days Post-vaccination|SARS-CoV-2 Neutralizing Antibody Titers as Assessed by Virus Neutralization Assay (VNA)|SARS-CoV-2 Binding Antibodies Assessed by ELISA	Janssen Vaccines & Prevention B.V.	All	18 Years and older   (Adult, Older Adult)	Phase 3	60000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	CR108876|VAC31518COV3001	September 7, 2020	March 10, 2023	March 10, 2023	August 10, 2020		October 14, 2020	Synexus Clinical Research US, Inc, Birmingham, Alabama, United States|University of Alabama Birmingham, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Alabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States|Optimal Research, Huntsville, Alabama, United States|Coastal Clinical Research, Inc, Mobile, Alabama, United States|VA Medical Center, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Synexus Clinical Research US, Inc, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Ark Clinical Research, Long Beach, California, United States|Anthony Mills Medical, Inc, Los Angeles, California, United States|East Bay AIDS Center (EBAC) CRS, Oakland, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSD Antiviral Research Center AVRC, San Diego, California, United States|Wr-McCr, Llc, San Diego, California, United States|VA Medical Center, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Denver, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale Medical Group, New Haven, Connecticut, United States|Alliance for Multispeciality Research, Coral Gables, Florida, United States|North Florida South Georgia Veteran Health System, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Research Centers of America, LLC, Hollywood, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|University of Miami- Jackson Memorial Hospital, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Advent Health Orlando, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|James A Haley VA Hospital GNS, Tampa, Florida, United States|Synexus Clinical Research US, Inc, The Villages, Florida, United States|Emory University of Medicine, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Jesse Brown VAMC Department of Surgery, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The Core Center, Chicago, Illinois, United States|University of IL Chicago, Chicago, Illinois, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|Optimal Research, Peoria, Illinois, United States|Indiana University Adult Cystic Fibrosis Center, Indianapolis, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Brigham and Women's Hospital, Inc., Boston, Massachusetts, United States|Fenway Health, Boston, Massachusetts, United States|University of Michigan Neuorsurgery A. Alfred Taubman Health Care Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Cherry Street Services, Inc., Grand Rapids, Michigan, United States|Abbott Northwestern Hospital Clinic, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|The Center For Pharmaceutical Research, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Meridian Clinical Research - Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Bronx Veterans Affairs Medical Center, Bronx, New York, United States|Bronx Prevention Research Center CRS, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|New York Blood Center, New York, New York, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Tryon Medical Group, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Durham VAMC, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc, Akron, Ohio, United States|CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Synexus Clinical Research US, Inc, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|VA Medical Center, Columbia, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Avera Health, Harrisburg, South Dakota, United States|PMG Research of Bristol, Bristol, Tennessee, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Clinical Research Associates Inc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Optimal Research, LLC, Austin, Texas, United States|AIDS Arms Incorporated Trinity Health and Wellness Center, Dallas, Texas, United States|Synexus Clinical Research US, Inc, Dallas, Texas, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University Of Texas Medical School At Houston, Houston, Texas, United States|Gordon Crofoot, MD, Houston, Texas, United States|Synexus Clinical Research US, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, Murray, Utah, United States|Health Research of Hampton Roads, Inc, Newport News, Virginia, United States|Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States|CIPREC, Buenos Aires, Argentina|Helios Salud Sa, Buenos Aires, Argentina|CEMEDIC, Buenos Aires, Argentina|Centro Medico Viamonte SRL, Ciudad Autonoma Buenos Aires, Argentina|Clinical Trials Division-Stamboulian Servicios de Salud, Ciudad Autonoma Buenos Aires, Argentina|Clínica y Maternidad Suizo Argentina, Ciudad Autonoma de Buenos Aires, Argentina|Fundacion Huesped, Ciudad Autonoma De Buenos Aire, Argentina|CEMIC Saavedra, Ciudad de Buenos Aires, Argentina|Hospital J. M. Ramos Mejía, Ciudad de Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|DIM Clinica Privada, Ramos Mejia, Argentina|Faculdade de Medicina Barretos FACISB, Barretos, Brazil|Hospital Das Clinicas Da Universidade Federal De Minas Gerais, Belo Horizonte, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil|L2IP - Instituto de Pesquisas Clínicas, Brasília, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|Fundação Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil|Hospital São José, Criciúma, Brazil|Oncovida - Centro de Onco-Hematologia de Mato Grosso, Cuiabá, Brazil|Hospital Nossa Senhora Das Gracas, Curitiba, Brazil|Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, Brazil|IEC - Instituto Evandro Chagas, Para, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirão Preto, Brazil|Hospital federal dos servidores do estado, Rio de Janeiro, Brazil|Instituto Brasil de Pesquisa Clinica, Rio de Janeiro, Brazil|FIO CRUZ- Fundação Oswaldo Cruz - Inst de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil|Hospital Geral De Nova Igaucu Brazil, Rio de Janeiro, Brazil|Fundação Bahiana De Infectologia, Salvador, Brazil|Obras Sociais Irma Dulce, Salvador, Brazil|Hospital da Universidade Federal de Santa Maria CEP/UFSM, Santa Maria, Brazil|Universidade Municipal de Sao Caetano do Sul, Sao Caetano do Sul, Brazil|Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil|Centro de Referência E Treinamento Dst/Aids, Sao Paulo, Brazil|CPQuali Pesquisa Clinica LTDA ME, São Paulo, Brazil|Instituto de infectologia Emilio Ribas, São Paulo, Brazil|Hospital Sirio Libanes, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil|Cepic - Centro Paulista De Investigacao Clinica, São Paulo, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil|Bioclinica Santiago Bulnes, Santiago, Chile|Facultad de Medicina Universidad de Chile, Santiago, Chile|Hospital Padre Hurtado, Santiago, Chile|Clinica del Maule, Talca, Chile|Hospital Dr Hernan Henriquez Aravena, Temuco, Chile|Centro de Estudios Clínicos V Región Ltda, Viña del Mar, Chile|Clinica de la Costa, Barranquilla, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Colombia|Hospital Universidad del Norte, Barranquilla, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Bogota, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Asistencia Cientifica de Alta Complejidad S.A.S, Bogota, Colombia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Medplus Medicina Prepagada S.A., Bogota, Colombia|Centro de Investigaciones Clinicas S.A.S., Cali, Colombia|Fundación Valle del Lili, Cali, Colombia|Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca, Floridablanca, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Programa de Estudio y Control de Enfermedades Tropicales, Medellin, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia|Hospital Pablo Tobon Uribe, Medellín, Colombia|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico|Instituto Nacional de Salud Publica, Cuernavaca, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico|Unidad de Atención Medica e Investigacion en Salud (UNAMIS), Merida, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital General Dr. Manuel Gea González, Mexico City, Mexico|Centro Medico Nacional Siglo XXI IMSS, Mexico, Mexico|CAIMED Investigacion en salud S.A de C.V., Mexico, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico|Hospital Universitario de Nuevo Leon 'Dr Jose Eleuterio Gonzalez', Monterrey, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Infectolab, Tijuana, Mexico|Centro de Invetigaciones Medicas, Callao, Peru|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Centro de Investigaciones Tecnologicas, Biomedica y medio ambientales (CITBM), Callao, Peru|Asociacion Civil Selva Amazonica (ACSA), Iquitos, Peru|Asociacion Civil Impacta Salud y Educacion - Barranco, Lima - Barranco, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil Via Libre, Lima, Peru|Instituto de Investigacion Nutricional, Lima, Peru|Asociacion Civil Impacta Salud y Educacion- San Miguel CRS, Lima, Peru|Chong Hua Hospital, Cebu City, Philippines|Josha Research, Bloemfontein, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|Family Clinical Research Unit FAM-CRU, Cape Town, South Africa|TASK Central, Cape Town, South Africa|Desmond Tutu HIV Foundation, Cape Town, South Africa|University of Cape Town IDM/CIDRI Research Site, Cape Town, South Africa|Desmond Tutu Hiv Foundation - University of Cape Town, Cape Town, South Africa|Masiphumelele Research Centre, Cape Town, South Africa|Ndlovu Elandsdoorn Site, Dennilton, South Africa|SA Medical Research Council, Durban, South Africa|SA Medical Research Council, Durban, South Africa|South African Medical Research Council Isipingo Clinical Research Site, Isipingo Rail, South Africa|CRISMO Bertha Gxowa Research Centre, Johannesburg, South Africa|Shandukani Research Centre, Johannesburg, South Africa|The Aurum Institute Klerksdorp Clinical Research Centre, Klerksdorp, South Africa|Qhakaza Mbokodo Research Centre, KwaZulu-Natal, South Africa|South African Medical Research Council Chatsworth Clinical Research Site, KwaZulu-Natal, South Africa|Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal, South Africa|Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Nelson Mandela Academic Clinical Research Unit 'NeMACRU', Mthatha, South Africa|PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa|MeCRU Clinical Research Unit, Pretoria, South Africa|Synexus Watermeyer, Pretoria, South Africa|The Aurum Institute Rustenburg Clinical Research Site, Rustenburg, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Perinatal HIV Research Unit (PHRU), Kliptown, Soweto, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa|The Aurum Institute: Tembisa - Clinic 4, Tembisa, South Africa|CAPRISA Vulindlela Clinic, Vulindlela, South Africa|University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng, South Africa|SATVI, Brewelskloof Hospital, Worcester, South Africa|Chernivtsi Regional Endocrinological Center Bukovinsky SMU, Chernivtsi, Ukraine|Poltava Regional Clinical Hospital HSEI of Ukraine Ukrainian Medical Stomatological Academy, Poltava, Ukraine|ME 'Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky of the Poltava Regional Council', Poltava, Ukraine|Zhytomyr Central City Hospital #1, Zhytomyr, Ukraine		https://ClinicalTrials.gov/show/NCT04505722
10	NCT04470427	A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19		Recruiting	No Results Available	SARS-CoV-2	Biological: mRNA-1273|Biological: Placebo	Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273|Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal|Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited AEs|Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of mRNA-1273|Number of Participants with a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection regardless of symptomatology or Severity Starting 14 Days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a Secondary Case Definition of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo regardless of evidence of prior SARS-CoV-2 Infection|Number of Participants with a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb|Quantified Levels or GMT of S Protein-Specific Binding Antibody (bAb)|GMFR of S Protein Specific bAb	ModernaTX, Inc.|Biomedical Advanced Research and Development Authority|National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years and older   (Adult, Older Adult)	Phase 3	30000	Industry|U.S. Fed|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	mRNA-1273-P301|75A50120C00034	July 27, 2020	October 27, 2022	October 27, 2022	July 14, 2020		September 28, 2020	Ascension St. Vincent Birmingham, Birmingham, Alabama, United States|Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States|Hope Research Institute, Chandler, Arizona, United States|Synexus Clinical Research US, Inc. - Phoenix West, Glendale, Arizona, United States|Hope Research Institute, Peoria, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Quality of Life Medical and Research Center, Tucson, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Advanced Clinical Research - Rancho Paseo, Banning, California, United States|University of California San Diego, La Jolla, California, United States|eStudySite - La Mesa, La Mesa, California, United States|UCLA Vine Street Clinic CRS, Los Angeles, California, United States|VA Greater Los Angeles Healthcare (veterans only), Los Angeles, California, United States|Paradigm Clinical Research Institute Inc, Redding, California, United States|Benchmark Research - Sacramento, Sacramento, California, United States|Medical Center For Clinical Research - M3 Wake Research, San Diego, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Lynn Institute of The Rockies, Colorado Springs, Colorado, United States|George Washington University, Washington, District of Columbia, United States|Accel Research Site, DeLand, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Synexus - Optimal Research - Melbourne, Melbourne, Florida, United States|Suncoast Research Group, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Synexus Clinical Research US, Inc. - Orlando, Orlando, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Hope Clinic of The Emory Vaccine Center, Decatur, Georgia, United States|Meridian Clinical Research, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Synexus Clinical Research US, Inc. - Chicago, Chicago, Illinois, United States|UIC Project WISH CRS, Chicago, Illinois, United States|University of Chicago-Hospital, Chicago, Illinois, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Alliance for Multispecialty Research, Newton, Kansas, United States|Alliance for Multispecialty Research- East Wichita, Wichita, Kansas, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|Benchmark Research - Metairie, Metairie, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Synexus - Optimal Research - Rockville, Rockville, Maryland, United States|Meridian Clinical Research, Rockville, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|MediSync Clinical Research Hattiesburg Clinic, Petal, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Meridian Clinical Research, Grand Island, Nebraska, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|AB Clinical Trials, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New Jersey Medical School, Newark, New Jersey, United States|Meridian Clinical Research, Binghamton, New York, United States|Weill Cornell Chelsea - (CRS), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Tryon Medical Partners, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research - M3 Wake Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc - M3 Wake, Raleigh, North Carolina, United States|Trial Management Associates, Wilmington, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc. - Cincinnati, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Cincinnati CRS, Cincinnati, Ohio, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Crisor, Medford, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC University Center, Pittsburgh, Pennsylvania, United States|Keystone VitaLink Research, Anderson, South Carolina, United States|Keystone VitaLink Research - Greenville, Greenville, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Keystone VitaLink Research - Spartanburg, Spartanburg, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|WR-ClinSearch, Chattanooga, Tennessee, United States|Alliance for Multispecialty Research, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Medical Arts Building, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Medical Center North, Nashville, Tennessee, United States|Benchmark Research - Austin, Austin, Texas, United States|Synexus - Optimal Research - Austin, Austin, Texas, United States|Tekton Research, Austin, Texas, United States|Advanced Clinical Research - Be Well MD, Cedar Park, Texas, United States|Global Medical Research - M3 Wake Research, Dallas, Texas, United States|Synexus Clinical Research US, Inc. - Dallas, Dallas, Texas, United States|Benchmark Research - Fort Worth, Fort Worth, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|DM Clinical Research - Texas Center For Drug Development, Houston, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|Centex Studies, McAllen, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Synexus Clinical Research US, Inc. - Salt Lake City, Murray, Utah, United States|Foothill Family Clinic - North, Salt Lake City, Utah, United States|Foothill Family Clinic-South Clinic, Salt Lake City, Utah, United States|Kaiser Permanente - Seattle, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04470427
11	NCT04456595	Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals	PROFISCOV	Recruiting	No Results Available	COVID-19	Biological: Adsorbed COVID-19 (inactivated) Vaccine|Biological: Placebo	Incidence of COVID-19 cases after two-doses immunization schedule|Frequency of adverse events up to seven days after immunization|Incidence of COVID-19 cases after 14-days of first immunization|Incidence of COVID-19 cases after 14-days of last immunization|Combined incidence of SARS-CoV-2 infection|Frequency of adverse events up to 28 days after immunization|Incidence of severe COVID-19 cases|Seroconversion rate|Cell-mediated immune profile	Butantan Institute|Sinovac Life Sciences Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 3	8870	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	COV-02-IB	July 21, 2020	September 2021	October 2021	July 2, 2020		August 4, 2020	Universidade de Brasília, Brasilia, DF, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital das Clínicas da Universidade Federal do Paraná, Curitiba, PR, Brazil|Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, RS, Brazil|Hospital das Clínicas da UNICAMP, Campinas, SP, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirao Preto, SP, Brazil|Instituto de Infectologia Emílio Ribas, Sao Paulo, SP, Brazil|Centro de Pesquisas Clínicas do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil|Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, SP, Brazil|Universidade Municipal de São Caetano do Sul, São Caetano do Sul, SP, Brazil|Faculdade de Medicina de São José do Rio Preto - FAMERP, São José Do Rio Preto, São Paulo, Brazil|Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil		https://ClinicalTrials.gov/show/NCT04456595
12	NCT04368728	Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals		Recruiting	No Results Available	SARS-CoV-2 Infection|COVID-19	Biological: BNT162b1|Biological: BNT162b2|Other: Placebo	Percentage of participants in Phase 1 reporting local reactions|Percentage of participants in Phase 1 reporting systemic events|Percentage of participants in Phase 1 reporting adverse events|Percentage of participants in Phase 1 reporting serious adverse events|Percentage of Phase 1 participants with abnormal hematology and chemistry laboratory values|Percentage of Phase 1 participants with grading shifts in hematology and chemistry laboratory assessments|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting local reactions|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting systemic events|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting adverse events|In the first 360 participants randomized into Phase 2/3, percentage of participants reporting serious adverse events|In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting local reactions|In a subset of at least 6000 participants randomized in Phase 2/3, percentage of participants reporting systemic events|Percentage of participants in Phase 2/3 reporting adverse events|Percentage of participants in Phase 2/3 reporting serious adverse events|Confirmed COVID-19 in Phase 2/3 participants without evidence of infection before vaccination|Confirmed COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination|In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|In Phase 1 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point|Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels|In Phase 1 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs|Proportion of participants in Phase 1 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels|In Phase 1 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point|In Phase 1 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels|Confirmed severe COVID-19 in Phase 2/3 participants without evidence of infection before vaccination|Confirmed severe COVID-19 in Phase 2/3 participants with and without evidence of infection before vaccination|Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants without evidence of infection before vaccination|Confirmed COVID-19 (according to the CDC-defined symptoms) in Phase 2/3 participants with and without evidence of infection before vaccination	BioNTech SE|Pfizer	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2|Phase 3	43998	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	C4591001|2020-002641-42	April 29, 2020	June 13, 2021	December 11, 2022	April 30, 2020		September 29, 2020	North Alabama Research Center, LLC, Athens, Alabama, United States|Birmingham Clinical Research Unit, Birmingham, Alabama, United States|Medical Affiliated Research Center, Huntsville, Alabama, United States|Optimal Research, LLC, Huntsville, Alabama, United States|Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States|Chinle Comprehensive Health Care Facility, Chinle, Arizona, United States|Johns Hopkins Center for American Indian Health, Chinle, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|The Pain Center of Arizona, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Collaborative Neuroscience Research, LLC, Garden Grove, California, United States|Collaborative Neuroscience Research, LLC, Long Beach, California, United States|Long Beach Clinical Trials Services Inc., Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Providence Clinical Research, North Hollywood, California, United States|Paradigm Clinical Research Center, Redding, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|Kaiser Permanente Santa Clara, Santa Clara, California, United States|Bayview Research Group, Valley Village, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Clinical Research Consulting, LLC, Milford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital; Investigational Drug Service, New Haven, Connecticut, United States|Yale Center for Clinical Investigations (CSRU), New Haven, Connecticut, United States|Alliance for Multispecialty Research, LLC-Coral Gable, Coral Gables, Florida, United States|DeLand Clinical Research Unit, DeLand, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Acevedo Clinical Research Associates, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|IACT Health, Columbus, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Solaris Clinical Research, Meridian, Idaho, United States|Optimal Research, LLC, Peoria, Illinois, United States|University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Alliance for Multispecialty Research, LLC, Newton, Kansas, United States|Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States|Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|LSUHSC-Shreveport Clinical Trials Office, Shreveport, Louisiana, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Pharmaron CPC, Inc., Baltimore, Maryland, United States|University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Michigan Center for Medical Research, Farmington Hills, Michigan, United States|MedPharmics, LLC, Gulfport, Mississippi, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research, Bozeman, Montana, United States|Methodist Physicians Clinic / CCT Research, Fremont, Nebraska, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Wr-Crcn, Llc, Las Vegas, Nevada, United States|Amici Clinical Research, Raritan, New Jersey, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Gallup Indian Medical Center, Gallup, New Mexico, United States|Johns Hopkins Center for American Indian Health, Gallup, New Mexico, United States|Johns Hopkins Center for American Indian Health, Shiprock, New Mexico, United States|Northern Navajo Medical Center, Shiprock, New Mexico, United States|Meridian Clinical Research, LLC, Binghamton, New York, United States|Meridian Clinical Research, Endwell, New York, United States|NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai - Investigational Drug Service, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|PMG Research of Charlotte LLC, Charlotte, North Carolina, United States|Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Duke Investigational Drug Service Pharmacy, Durham, North Carolina, United States|Duke University Medicine Circle- Duke Early Phase Clinical Research Unit, Durham, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|PriMED Clinical Research, Dayton, Ohio, United States|Senders Pediatrics, South Euclid, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Kaiser Permanente Northwest-Center for Health Research, Portland, Oregon, United States|Lehigh Valley Health Network/Network Office of Research and Innovation, Allentown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Main Street Physician's Care, Little River, South Carolina, United States|Main Street Physician's Care, Loris, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|Trinity Clinical Research, Tullahoma, Tennessee, United States|Benchmark Research, Austin, Texas, United States|ARC Clinical Research at Wilson Parke, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|North Texas Infectious Diseases Consultants, P.A., Dallas, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Texas Health Family Care, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Dr. Van Tran Family Practice, Houston, Texas, United States|Hany H. Ahmed, MD, Houston, Texas, United States|Ventavia Research Group, LLC, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Ventavia Research Group, LLC, Keller, Texas, United States|SMS Clinical Research, LLC, Mesquite, Texas, United States|LinQ Research, LLC, Pearland, Texas, United States|Benchmark Research - Intake Facility, San Angelo, Texas, United States|Benchmark Research., San Angelo, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States|Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale, Virginia, United States|Infectious Diseases Physicians, LLC, Annandale, Virginia, United States|Virginia Research Center LLC, Midlothian, Virginia, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|Wenatchee Valley Hospital, Wenatchee, Washington, United States|Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Caba, Argentina|Hospital Santo Antonio/ Associacao Obras Sociais Irma Dulce, Salvador, BA, Brazil|CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda (Casa Branca), São Paulo, Brazil|Newtown Clinical Research Centre, Johannesburg, Gauteng, South Africa|Jongaie Research, Pretoria, Gauteng, South Africa|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa|Tiervlei Trial Centre, Basement Level, Karl Bremer Hospital, Cape Town, Western CAPE, South Africa|Ankara Universitesi Tip Fakultesi, Ibni Sina Hastanesi, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi-Cerrahpasa, Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Medipol Mega Universite Hastanesi, Istanbul, Turkey|Acibadem Atakent Hastanesi, Istanbul, Turkey|Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi, Sakarya, Turkey		https://ClinicalTrials.gov/show/NCT04368728
